Levetiracetam for Canine Idiopathic Epilepsy: Comparative Outcomes, Serum Monitoring, and Intranasal Emergency Use

Bottom line

• Levetiracetam is a second-generation antiseizure medication (SV2A ligand) used in dogs as both add-on and monotherapy, valued for a wide safety margin and minimal hepatic metabolism.
• In a 100-dog comparative study, caregiver-assessed outcomes with levetiracetam, zonisamide, or phenobarbital monotherapy were broadly similar, with quality-of-life gains across all three and the highest adverse-effect burden reported for phenobarbital [1].
• Phenobarbital co-administration measurably lowers serum levetiracetam concentrations, so dogs on combined therapy frequently need higher levetiracetam exposure to reach concentrations considered effective in people [2].
• Weight gain is a class effect, not an incidental finding: antiseizure-drug use was the single largest modeled driver of food motivation (effect size 32%) and greater adiposity across 222 epileptic dogs — counsel on body condition at initiation [4].
• No validated canine therapeutic range exists; dosing is extrapolated from human targets and individualized clinically. Confirm all dosing against a current formulary.

Drug facts

• Class: Second-generation antiseizure medication (racetam; SV2A ligand)
• Mechanism: Binds synaptic vesicle protein 2A (SV2A), modulating synaptic neurotransmitter release (label-supported mechanism)
• Route/interval: Oral and parenteral formulations exist, including immediate- and extended-release oral products; intranasal use is investigational. Defer interval and dose to a current formulary.
• Indication: Off-label in dogs for idiopathic epilepsy, as add-on therapy and monotherapy; not FDA-approved for veterinary use
• Approval: Human drug (levetiracetam, originally Keppra); no veterinary FDA approval
• Label contraindications: Per human label, known hypersensitivity; use cautiously with significant renal impairment (renally cleared)
• Label common AEs: Sedation and transient behavioral or gastrointestinal effects are the most commonly reported in dogs; serious adverse effects are uncommon

How does levetiracetam compare with zonisamide and phenobarbital?

The most direct comparison of levetiracetam against the two other commonly used canine antiseizure drugs comes from a retrospective study with a caregiver questionnaire. As of July 2026, this remains the central comparative dataset. Gristina and colleagues (2023) evaluated 100 dogs with idiopathic epilepsy treated with levetiracetam (n = 34), zonisamide (n = 31), or phenobarbital (n = 35) as monotherapy, drawing on medical-record review and owner survey responses [1].

Across all three drugs, owners reported a significant improvement in mean quality-of-life score during monotherapy (7.7; SD 2.14) compared with before treatment (6.25; SD 2.63; P < .0001), with no difference identified between the three monotherapy groups. The pattern of adverse effects did differ by drug: reported adverse effects were significantly more common in the phenobarbital group (77%, 27 of 35) and least common in the zonisamide group (39%, 12 of 31; P = .0066). Treatment-failure rates were 51% for phenobarbital, 35% for levetiracetam, and 45% for zonisamide, with failure most often attributed to inadequate seizure control; no significant difference was identified between groups in the rate of or time to failure.

The authors concluded that most caregivers reported a favorable outcome with any of the three monotherapies, that phenobarbital carried the highest reported burden of adverse effects without a corresponding difference in quality of life, and that prospective controlled studies are still needed to compare efficacy and safety directly. This is the central caveat for interpreting levetiracetam monotherapy: the supporting human-extrapolated and observational evidence is encouraging but not yet confirmed by controlled veterinary trials.

Serum concentrations, the phenobarbital interaction, and the absent canine therapeutic range

A practical obstacle to levetiracetam dosing in dogs is that the factors governing its serum concentrations — and any target range — are poorly defined. Saint-Maxent and colleagues (2024) examined 69 client-owned dogs with epilepsy treated with levetiracetam alone or in combination, using 127 trough serum levetiracetam measurements [2].

Two findings are clinically important. First, the oral dose was the strongest determinant of serum concentration, and that relationship was stronger under monotherapy. Second, phenobarbital significantly decreased serum levetiracetam concentration in a dose-dependent manner — a recognized enzyme-induction interaction. As a result, dogs receiving both drugs generally require substantially higher levetiracetam exposure to reach the serum concentrations regarded as therapeutic in people. Critically, the investigators could not identify a discrete therapeutic range from their data.

The clinical translation is that levetiracetam monitoring in dogs cannot lean on a validated canine reference interval the way phenobarbital or bromide monitoring can. Where monitoring is used, trough sampling and attention to concurrent phenobarbital are the levers that matter most; the numeric dose itself should be set from a current formulary and individualized, not from any figure reproduced here.

Intranasal levetiracetam for emergency seizure management

Cluster seizures and status epilepticus demand rapid drug delivery, and intravenous access is not always available. Intranasal benzodiazepines are established for early seizure cessation, but longer-acting agents had not been characterized by this route in dogs until recently. Wagner and colleagues (2026) described the single-dose pharmacokinetics of a compounded intranasal levetiracetam product in nine healthy dogs in a randomized crossover design against an intravenous dose [3].

The intranasal route achieved minimum target concentrations (defined in the study as the lower reference of 5 micrograms/mL) rapidly — within roughly the first half-hour on average — and maintained them for several hours, with a bioavailability of about 70%. The authors noted, however, that a single intranasal dose did not reach the high end of the reference interval in any dog, concluding that intranasal levetiracetam may be a viable alternative for emergent seizure management when intravenous access is unavailable, but that multiple doses may be required to achieve seizure cessation in some patients. This positions intranasal levetiracetam as a promising bridging option pending larger and clinical-outcome studies, rather than an established protocol. It is not yet a substitute for established benzodiazepine-based seizure-emergency protocols.

Safety and the weight-gain trade-off: food motivation as a class effect

Beyond the sedation and transient behavioral or gastrointestinal effects most commonly reported with levetiracetam, appetite and weight gain are a long-recognized but under-appreciated consequence of antiseizure therapy — and one now quantified at the class level. Morros-Nuevo and colleagues (2024) used a validated obesity-risk questionnaire to compare food motivation in 222 dogs with idiopathic epilepsy against 7,086 healthy dogs [4].

Dogs with idiopathic epilepsy receiving antiseizure drugs had significantly higher food motivation than healthy dogs, and their caregivers reported significantly greater interventional effort and food restriction — yet the dogs still had significantly higher adiposity. Within the epileptic group, antiseizure-drug use had the largest modeled impact on food motivation, with an effect size of 32%; the authors concluded that antiseizure drugs increase food motivation, resulting in greater adiposity.

Two caveats bound the finding. The sample size did not allow the team to separate the effect of individual drugs, and the data were caregiver-reported, so this describes a class-level association rather than implicating levetiracetam specifically. The practical implication is nonetheless direct: heightened food-seeking should be framed to owners as a drug effect, not simply a behavior problem, and structured feeding with body-condition monitoring may be needed even when seizures are well controlled.

Multimodal and adjunct directions in drug-resistant epilepsy

Roughly a third of dogs with idiopathic epilepsy remain inadequately controlled on antiseizure drugs, which has driven interest in non-pharmacologic and metabolic adjuncts. Three distinct lines of evidence, all early-stage, shape that conversation as of July 2026.

Neurostimulation (rTMS). Charalambous and colleagues (2025) ran a single-blinded, randomized, sham-controlled trial of a novel three-day repetitive transcranial magnetic stimulation (rTMS) protocol in 20 dogs with drug-resistant idiopathic epilepsy or epilepsy of unknown origin, allocated to active (n = 10) or sham (n = 10) stimulation [5]. Median monthly seizure frequency was lower in the active group (8, range 0–24) than sham (17, range 7–46; P = 0.04), as was monthly seizure-day frequency (active 8 vs sham 11; P = 0.04). The number of cluster seizures was significantly lower with active rTMS (10, range 5–23) versus sham (16, range 10–25; P = 0.005), and no adverse events were reported. The authors caution that a one-size-fits-all protocol is likely to give suboptimal results because the effect depends heavily on stimulation parameters and individual variability — this is a pilot-scale proof-of-concept, not a practice-changing result.

Cannabidiol. The same drug-resistant population anchored an earlier double-blinded crossover trial of adjunct cannabidiol in 51 dogs, in which dogs had to have at least two seizures per month while receiving at least one antiseizure drug (Rozental 2023) [6]. That trial underscores both the magnitude of unmet need in this group and the crossover design increasingly used to evaluate adjuncts against a hard-to-treat baseline.

Metabolic and gut-brain targets. Moving upstream of the CNS, Cabri and colleagues (2026) published a PRISMA-ScR scoping review of studies reporting metabolic, immunometabolic, or neurochemical alterations in canine idiopathic epilepsy diagnosed by IVETF consensus criteria versus healthy controls [7]. Consistent alterations spanned amino acid and lipid metabolism, micronutrients, neurotransmission, oxidative stress, inflammation, endocannabinoid signalling, microRNAs, and gut-brain axis pathways — paralleling human epilepsy. The authors flagged dietary and metabolic approaches (for example, medium-chain triglyceride supplementation), microbiome modulation, and immunometabolic targeting as mechanism-based intervention candidates. They are explicit that current evidence is limited by small, heterogeneous cohorts, confounding by antiseizure medications, dietary and fasting variability, breed effects, and a predominance of associative over causal relationships. These are research directions, not established protocols, and — unlike phenobarbital or bromide — they carry no therapeutic-drug-monitoring framework.

Contraindications, precautions, and pharmacokinetics

• Renal clearance. Levetiracetam is predominantly renally cleared with minimal hepatic metabolism, which is part of its appeal in patients with hepatic concerns; the human label advises caution with significant renal impairment.
• Hypersensitivity. Known hypersensitivity is the label contraindication.
• Phenobarbital interaction. Enzyme induction by phenobarbital lowers serum levetiracetam in a dose-dependent manner [2]; dogs on combination therapy generally need higher levetiracetam exposure than on monotherapy.
• No validated canine reference range. Targets are extrapolated from human concentrations; there is no discrete canine therapeutic interval [2]. Trough sampling and attention to concurrent phenobarbital are the useful monitoring levers.
• Body condition. Because antiseizure drugs as a class raise food motivation and adiposity [4], weight and body-condition monitoring should be built into the treatment plan.
• Dosing. All dose, interval, and target-concentration figures must be taken from a current formulary and individualized — nothing here is a prescribing instruction.

Practical decision support

• Choosing an agent. On current observational evidence, levetiracetam, zonisamide, and phenobarbital deliver broadly similar caregiver-assessed outcomes, with phenobarbital carrying the highest reported adverse-effect burden and no quality-of-life advantage [1]. Levetiracetam's minimal hepatic involvement makes it attractive where hepatic tolerability is a concern, at the cost of no validated monitoring range.
• Monitoring in context. A retrospective analysis of US primary-care practices (Pompermaier 2026, 853 dogs) documented that serum bromide was monitored in only 31.6% of dogs receiving potassium bromide, versus 77.5% monitoring for phenobarbital — a real-world reminder that even the agents with well-characterized reference ranges are under-monitored, while levetiracetam has no such range to anchor to [8].
• Combination therapy. When adding phenobarbital, anticipate the need for higher levetiracetam exposure and use trough sampling to guide adjustment [2].
• Owner counseling at initiation. Set expectations about increased food-seeking and institute structured feeding plus body-condition monitoring from day one [4].
• Seizure emergencies. Intranasal levetiracetam is an encouraging early signal for when IV access is unavailable but is not yet a validated substitute for benzodiazepine-based protocols; multiple doses may be required [3].
• Refractory cases. For dogs breaking through conventional therapy, rTMS and metabolic/dietary adjuncts are worth tracking but should be framed to clients as investigational, without standardized protocols [5][7].

Frequently Asked Questions

Cited answers to the questions clinicians most often type appear in the FAQ block below and mirror the evidence synthesized above.

Changelog

• 2026-07-06: Consolidated the levetiracetam evergreen with three dated dispatches — the rTMS sham-controlled trial (Charalambous 2025), the antiseizure-drug food-motivation questionnaire study (Morros-Nuevo 2024), and the metabolic/gut-brain scoping review plus US primary-care TDM retrospective (Cabri 2026; Pompermaier 2026) — into a single hub. Each distinct study appears once.
• 2026-06-19: First published.